2022
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderVeterans Healthcare AdministrationFormulations of buprenorphineComparative effectiveness trialOpioid useEffectiveness trialUse disordersOpioid epidemicSublingual buprenorphine/naloxoneSevere opioid use disorderBuprenorphine/naloxoneUS opioid epidemicClinical effectiveness trialStandard of careEffective medication treatmentsExtended-release formulationUrgent clinical needLong-term trialsHepatitis BSecondary outcomesSevere sequelaeOpioid abstinencePrimary outcomeMedication treatmentTRIAL REGISTRATION
2021
Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study
Barocas JA, Savinkina A, Adams J, Jawa R, Weinstein ZM, Samet JH, Linas BP. Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. The Lancet Public Health 2021, 7: e56-e64. PMID: 34861189, PMCID: PMC8756295, DOI: 10.1016/s2468-2667(21)00248-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction consult serviceHospital-based strategiesUS opioid epidemicOpioid epidemicUse disordersConsult serviceProbabilistic sensitivity analysesClinical impactDrug useIncremental cost-effectiveness ratioInjection-related infectionsInjection drug useMean lifetime costsNational InstituteCost-effectiveness ratioHarm reduction servicesDeterministic sensitivity analysesInpatient prescribingObservational cohortRecurrent infectionsOutpatient treatmentClinical trialsOverdose riskMedicationsPrescribers’ satisfaction with delivering medications for opioid use disorder
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Kim H, Madden LM, Haram E, Molfenter T. Prescribers’ satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, And Policy 2021, 16: 78. PMID: 34663379, PMCID: PMC8521499, DOI: 10.1186/s13011-021-00413-7.Peer-Reviewed Original ResearchConceptsType of MOUDOpioid use disorderPrescriber satisfactionPrescriber characteristicsUse disordersXR-naltrexoneBuprenorphine treatmentExtended-release naltrexoneUS opioid epidemicOverall satisfactionRelease naltrexoneGreater overall satisfactionClinical trialsOpioid epidemicMethodsAs partMOUDWeb-based surveyPatient censusPrescribersMedicationsBuprenorphineDisordersTreatmentCurrent studyHigh levels
2020
Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
Barocas JA, Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clinical Infectious Diseases 2020, 73: e3661-e3669. PMID: 32901815, PMCID: PMC8662770, DOI: 10.1093/cid/ciaa1346.Peer-Reviewed Original ResearchConceptsInjection opioid useRisk of deathAge 60 yearsOpioid useInfective endocarditisOpioid epidemicMortality rateUS opioid epidemicSyringe services programLow-risk techniqueProbability of deathHarm reduction approachAttributable fractionRisk groupsNatural historyInjection behaviorModel-generated estimatesDeathOpioidsSignificant increaseInjection frequencyUnited StatesMortalityRiskEpidemicTemporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population
Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS. Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. Journal Of The National Cancer Institute 2020, 113: 274-281. PMID: 32785685, PMCID: PMC7936059, DOI: 10.1093/jnci/djaa110.Peer-Reviewed Original ResearchConceptsOpioid-prescribing ratesOpioid prescribingOpioid Prescribing PatternsOpioid-prescribing guidelinesUS opioid epidemicPalliative care providersMultivariable negative binomial regressionNoncancer populationsPrescribing patternsPrescribing ratesSymptom managementCancer survivorsOpioid epidemicDrug claimsCare providersMedicare populationMedicare beneficiariesPrescribingOncologistsNononcologistsNegative binomial regressionOpioidsBinomial regressionPatientsAnnual numberInconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery for Injection Drug Use-associated Infective Endocarditis.
Nguemeni Tiako MJ, Hong S, Bin Mahmood SU, Mori M, Mangi A, Yun J, Juthani-Mehta M, Geirsson A. Inconsistent Addiction Treatment for Patients Undergoing Cardiac Surgery for Injection Drug Use-associated Infective Endocarditis. Journal Of Addiction Medicine 2020, 14: e350-e354. PMID: 32732685, DOI: 10.1097/adm.0000000000000710.Peer-Reviewed Original ResearchConceptsActive drug useInjection drug use-associated infective endocarditisOpioid use disorderPsychosocial consultationAddiction treatmentDrug rehabilitation programInfective endocarditisRehabilitation programUse disordersDrug Use-Associated Infective EndocarditisDrug useEvidence of enrollmentTertiary care centerInjection drug useUS opioid epidemicDrug rehabilitationRehabilitation attendanceMost patientsCardiac surgeryRetrospective reviewCare centerOpioid epidemicPatientsMedicationsIDUs
2019
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply